Upper Limb Pain and Paresthesia in a Post-Stroke Patient Treated With
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Scalp Dysesthesia. Case Report Disestesia Do Escalpo
BrJP. São Paulo, 2020 jan-mar;3(1):86-7 CASE REPORT Scalp dysesthesia. Case report Disestesia do escalpo. Relato de caso Letícia Arrais Rocha1, João Batista Santos Garcia1, Thiago Alves Rodrigues1 DOI 10.5935/2595-0118.20200016 ABSTRACT RESUMO BACKGROUND AND OBJECTIVES: Scalp dysesthesia is JUSTIFICATIVA E OBJETIVOS: A disestesia do escalpo ca- characterized by the presence of several localized or diffuse symp- racteriza-se pela presença de diversos sintomas localizados ou toms, such as burning, pain, pruritus or stinging sensations, wi- difusos, como queimação, dor, prurido ou sensações de picada, thout objective findings in the physical examination of the pa- sem achados objetivos no exame físico do paciente que possam tient that can explain and link the existing symptomatology to explicar e ligar os sintomas existentes à alguma outra etiologia. some other etiology. The aim of this study was to describe a case O objetivo deste estudo foi descrever um caso de disestesia de of scalp dysesthesia, from its clinical and laboratory investigation escalpo, desde a sua investigação clínica e laboratorial, até a con- and the conduct adopted. duta adotada. CASE REPORT: A 38-year-old male patient, first assigned to RELATO DO CASO: Paciente do sexo masculino, 38 anos. Pri- the Dermatology Service, with complaints of pruritus in the meiramente foi ao serviço de Dermatologia com queixa de pru- scalp for 5 years. In the consultation at the Pain Service, the pa- rido em couro cabeludo há cinco anos. Na consulta do Serviço tient complained of daily, intermittent and burning dysesthetic de Dor, o paciente queixava-se de sensações disestésicas como: sensations, such as tingling and pruritus in the bipariethoccipital formigamento e prurido em região biparieto-occipital que piora region, worsening with heat and associated with severe pain in com o calor, associada à dor de forte intensidade, diária, intermi- the cervical region. -
Pain and Dysesthesia in Patients with Spinal Cord Injury: a Postal Survey
Spinal Cord (2001) 39, 256 ± 262 ã 2001 International Medical Society of Paraplegia All rights reserved 1362 ± 4393/01 $15.00 www.nature.com/sc Original Article Pain and dysesthesia in patients with spinal cord injury: A postal survey NB Finnerup*,1, IL Johannesen2, SH Sindrup3, FW Bach1 and TS Jensen1 1Department of Neurology and Danish Pain Research Centre, University Hospital of Aarhus, Denmark; 2Department of Rheumatology, Viborg Hospital, Denmark; 3Department of Neurology, Odense University Hospital, Denmark Study design: A postal survey. Objectives: To assess the prevalence and characteristics of pain and dysesthesia in a community based sample of patients with spinal cord injury (SCI) with special focus on neuropathic pain. Setting: Community. Western half of Denmark. Methods: We mailed a questionnaire to all outpatients (n=436) of the Viborg rehabilitation centre for spinal cord injury. The questionnaire contained questions regarding cause and level of spinal injury and amount of sensory and motor function below this level. The words pain and unpleasant sensations were used to describe pain (P) and dysesthesia (D) respectively. Questions included location and intensity of chronic pain or dysesthesia, degree of interference with daily activity and sleep, presence of paroxysms and evoked pain or dysesthesia, temporal aspects, alleviating and aggravating factors, McGill Pain Questionnaire (MPQ) and treatment. Results: Seventy-six per cent of the patients returned the questionnaire, (230 males and 100 females). The ages ranged from 19 to 80 years (median 42.6 years) and time since spinal injury ranged from 0.5 to 39 years (median 9.3 years). The majority (475%) of patients had traumatic spinal cord injury. -
Chemotherapy-Induced Neuropathy and Diabetes: a Scoping Review
Review Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review Mar Sempere-Bigorra 1,2 , Iván Julián-Rochina 1,2 and Omar Cauli 1,2,* 1 Department of Nursing, University of Valencia, 46010 Valencia, Spain; [email protected] (M.S.-B.); [email protected] (I.J.-R.) 2 Frailty Research Organized Group (FROG), University of Valencia, 46010 Valencia, Spain * Correspondence: [email protected] Abstract: Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. -
Livedoid Vasculopathy Associated with Peripheral Neuropathy: a Report of Two Cases* Vasculopatia Livedoide Associada a Neuropatia Periférica: Relato De Dois Casos
CASE REPORT 227 s Livedoid vasculopathy associated with peripheral neuropathy: a report of two cases* Vasculopatia livedoide associada a neuropatia periférica: relato de dois casos Mariana Quirino Tubone1 Gabriela Fortes Escobar1 Juliano Peruzzo1 Pedro Schestatsky2 Gabriela Maldonado3 DOI: http://dx.doi.org/10.1590/abd1806-4841.20132363 Abstract: Livedoid vasculopathy (LV) is a chronic and recurrent disease consisting of livedo reticularis and sym- metric ulcerations, primarily located on the lower extremities, which heal slowly and leave an atrophic white scar ("atrophie blanche"). Neurological involvment is rare and presumed to be secondary to the ischemia from vascu- lar thrombosis of the vasa nervorum. Laboratory evaluation is needed to exclude secondary causes such as hyper- coagulable states, autoimmune disorders and neoplasms. We present two patients with a rare association of peripheral neuropathy and LV, thereby highlighting the importance of a multidisciplinary approach to reach the correct diagnosis. Keywords: Livedo reticularis; Mononeuropathies; Polyneuropathies; Skin diseases, vascular Resumo: Vasculopatia livedoide é uma doença crônica e recorrente caracterizada por livedo reticular e úlceras simétricas nos membros inferiores, que cicatrizam e deixam uma cicatriz branca atrófica ("atrophie blanche"). Envolvimento neurológico é raro e está provavelmente associado a isquemia pela trombose dos vasa nervorum. Avaliação laboratorial é indicada com o intuito de excluir causas secundárias como estados de hipercoagulabili- dade, doenças autoimunes e neoplasias. Apresentamos dois pacientes com uma rara associação de vasculopatia livedoide com neuropatia periférica, enfatizando a importância de uma abordagem multidisciplinar na busca do diagnóstico correto. Palavras-chave: Dermatopatias vasculares; Livedo reticular; Mononeuropatias; Polineuropatias INTRODUCTION Livedoid vasculopathy (LV) is a chronic and resentation of the dermo-hypodermic junction, was recurrent disease, usually restricted to the skin, and compatible with LV. -
Cerebral Venous Thrombosis and Livedo Reticularis in a Case with MTHFR 677TT Homozygote
Journal of Clinical Neurology / Volume 2 / June, 2006 Case Report Cerebral Venous Thrombosis and Livedo Reticularis in a Case with MTHFR 677TT Homozygote Jee-Young Lee, M.D., Manho Kim, M.D., Ph.D. Department of Neurology, College of Medicine, Seoul National University, Seoul, Korea Hyperhomocysteinemia associated with methylene terahydrofolate reductase (MTHFR) mutation can be a risk factor for idiopathic cerebral venous thrombosis. We describe the first case of MTHFR 677TT homozygote with cerebral venous thrombosis and livedo reticularis. A 45-year-old man presented with seizures and mottled-like skin lesions, that were aggravated by cold temperature. Hemorrhagic infarct in the right frontoparietal area with superior sagittal sinus thrombosis was observed. He had hyperhomocysteinemia, low plasma folate level, and MTHFR 677TT homozygote genotype, which might be associated with livedo reticularis and increase the risk for cerebral venous thrombosis. J Clin Neurol 2(2):137-140, 2006 Key Words : Livedo reticularis, Methylene tetrahydrofolate reductase, Cerebral venous thrombosis Hyperhomocysteinemia causes vascular endothelial venous infarct due to cerebral venous thrombosis. damage that result in atherosclerosis and ischemic strokes.1 It is also associated with prothrombotic state or venous thromboembolism2 including cerebral venous CASE REPORT thrombosis.3 Among the thrombophilic factors with hyperhomocysteinemia, methylene tetrahydrofolate reduc- A 45 year-old man was brought to the emergency tase (MTHFR) mutant (C677 → T, homozygote) with room with uncontrolled seizures. Two days ago, sudden low plasma folate concentration increases the risk for paresthesia in left arm developed, which progressed to cerebral venous thrombosis.4 MTHFR 677TT is thermo- tonic posturing and leftward head version, followed by labile and sensitive to temperature alteration.5 a generalized tonic clonic seizure. -
Neuromyotonia with Polyneuropathy, Prominent Psychoorganic Syndrome
Ehler and Meleková Journal of Medical Case Reports (2015) 9:101 DOI 10.1186/s13256-015-0581-0 JOURNAL OF MEDICAL CASE REPORTS CASE REPORT Open Access Neuromyotonia with polyneuropathy, prominent psychoorganic syndrome, insomnia, and suicidal behavior without antibodies: a case report Edvard Ehler* and Alena Meleková Abstract Introduction: Peripheral nerve hyperexcitability disorders are characterized by constant muscle fiber activity. Acquired neuromyotonia manifests clinically in cramps, fasciculations, and stiffness. In Morvan’s syndrome the signs of peripheral nerve hyperexcitability are accompanied by autonomic symptoms, sensory abnormalities, and brain disorders. Case presentation: A 70-year-old Caucasian man developed, in the course of 3 months, polyneuropathy with unpleasant dysesthesia of lower extremities and gradually increasing fasciculations, muscle stiffness and fatigue. Subsequently, he developed a prominent insomnia with increasing psychological changes and then he attempted a suicide. Electromyography confirmed a sensory-motor polyneuropathy of a demyelinating type. The findings included fasciculations as well as myokymia, doublets and multiplets, high frequency discharges, and afterdischarges, following motor nerve stimulation. No auto-antibodies were found either in his blood or cerebrospinal fluid. Magnetic resonance imaging of his brain showed small, unspecific, probably postischemic changes. A diagnosis of Morvan’s syndrome was confirmed; immunoglobulin (2g/kg body weight) was applied intravenously, and, subsequently, -
Chronic Cryptogenic Sensory Polyneuropathy Clinical and Laboratory Characteristics
ORIGINAL CONTRIBUTION Chronic Cryptogenic Sensory Polyneuropathy Clinical and Laboratory Characteristics Gil I. Wolfe, MD; Noel S. Baker, MD; Anthony A. Amato, MD; Carlayne E. Jackson, MD; Sharon P. Nations, MD; David S. Saperstein, MD; Choon H. Cha, MD; Jonathan S. Katz, MD; Wilson W. Bryan, MD; Richard J. Barohn, MD Background: Chronic sensory-predominant polyneu- duration of symptoms of 62.9 months. Symptoms al- ropathy (PN) is a common clinical problem confronting most always started in the feet and included distal numb- neurologists. Even with modern diagnostic approaches, ness or tingling in 86% of patients and pain in 72% of many of these PNs remain unclassified. patients. Despite the absence of motor symptoms at pre- sentation, results of motor nerve conduction studies were Objective: To better define the clinical and laboratory abnormal in 60% of patients, and electromyographic evi- characteristics of a large group of patients with crypto- dence of denervation was observed in 70% of patients. genic sensory polyneuropathy (CSPN) evaluated in 2 uni- Results of laboratory studies were consistent with axo- versity-based neuromuscular clinics. nal degeneration. Patients with and without pain were similar regarding physical findings and laboratory test ab- Design: Medical record review of patients evaluated normalities. Only a few patients (,5%) had no evi- for PN during a 2-year period. We defined CSPN on dence of large-fiber dysfunction on physical examina- the basis of pain, numbness, and tingling in the distal tion or electrophysiologic studies. All 66 patients who extremities without symptoms of weakness. Sensory had follow-up examinations (mean, 12.5 months) re- symptoms and signs had to evolve for at least 3 mained ambulatory. -
What Are Panic Attacks?
What are Panic Attacks? Understanding the body’s “Fight or Flight” response to a threat. We all have a built-in alarm system that turns on automatically to make sure we survive whatever danger triggers it. This alarm is a lot like a burglar alarm on a house; once it detects something that might be a threat, it automatically sets off several events. If someone were breaking into your house, you would want the alarm system to call the police immediately. You would also likely want to turn on lights and even sound an audible alarm to wake you and scare off the intruder. The brain’s alarm system sets off a series of events as well, commonly called the “fight or flight” response. The fight or flight response is meant to put us in a state of high alert so that we can fight off an enemy or flee to escape with our lives. This alarm makes us faster and stronger and more focused than we would normally be. Our ancestors may not have survived if the human body was not hardwired with the fight or flight response. The reaction is automatic. It helps us survive, and we do not have to think about it; it just happens. But because it is automatic, we do not get to choose which things will set it off. Sometimes, the fight or flight response can start firing if it thinks there is danger, even when there isn’t any real threat around. This is especially common in people who have been through a traumatic event. -
Livedoid Vasculopathy – Benefit of Intravenous Immunoglobulin in A
CASE REPORTS Ref: Ro J Rheumatol. 2021;30(1) DOI: 10.37897/RJR.2021.1.4 LIVEDOID VASCULOPATHY – BENEFIT OF INTRAVENOUS IMMUNOGLOBULIN IN A REFRACTORY CASE Stefan Cristian Dinescu1, Andreea Lili Barbulescu2, Paulina Lucia Ciurea1, Roxana Mihaela Dumitrascu3, Beatrice Andreea Chisalau3, Cristina Dorina Parvanescu3, Sineta Cristina Firulescu4, Florentin Ananu Vreju1 1 Department of Rheumatology, University of Medicine and Pharmacy, Craiova, Romania 2 Department of Pharmacology, University of Medicine and Pharmacy, Craiova, Romania 3Doctoral School, University of Medicine and Pharmacy, Craiova, Romania 4 Department of Rheumatology, Emergency County Hospital, Craiova, Romania Abstract Livedoid vasculopathy is a rare vascular disease which typically manifests as recurrent ulcerative lesions on the lower extremities. It is classified as a vasculopathy, not a true vasculitis, and defined as a vasooclusive syndrome, caused by non-inflammatory thrombosis of the upper and mid-dermal venulae. Main disorders associated with LV include thrombophilias, autoimmune diseases and neoplasia. A triad of clinical features is present in most patients and consist of livedo racemosa (less frequently livedo reticularis), ulcerations and atrophie blanche. Management generally relies on antiplatelet drugs, anticoagulants, vasodilators and fibrinolytic therapy. Some benefit has been observed with intravenous immunoglobulin, colchicine, hyperbaric oxygen, while glucocorticoids are efficient to a lesser extent. This case report highlights a refractory clinical form with no identifiable predisposing condition, which proved responsive only to intravenous immunoglobulin. Keywords: thrombosis, purpura, ulcer, intravenous immunoglobulins INTRODUCTION cal form with no identifiable predisposing condition, which proved responsive only to intravenous immu Livedoid vasculopathy (LV) is a rare vascular dis noglobulin. ease which typically manifests as recurrent ulcerative lesions on the lower extremities. -
Sneddon's Syndrome
DOI: 10.5272/jimab.14-1-2010.72 Journal of IMAB - Annual Proceeding (Scientific Papers) 2008, vol. 14, book 1 SNEDDON’S SYNDROME Valentin Valtchev1, Virginia Simeonova2 , Dimitar Gospodinov1, Ivelina Yordanova1, Valentina Dimitrova1, Verka Pavlova1, Emiliana Konova4, S. Popovska3 , Boyko Stamenov2 1Department of Dermatology and Venereology, 2Department of Neurology, 3Department of General and Clinical Pathology, 4Department of Immunology, Medical University – Pleven, Bulgaria ABSTRACT pressure and migraine for 10 years. She has been having Sneddon’s syndrome is usually characterized by the persistent cutaneous lesions on the upper and lower association of an ischemic cerebrovascular disease and a extremities and trunk for the last 20 years. widespread livedo reticularis. The incidence of Sneddon At physical examination, a slight elevation in syndrome is 4/1000 000. We present 42-year-old woman with pressure levels (150 x 80mm Hg), III degree obesity and livedo reticularis, recurrence ischaemic cerebrovascular slight edema of the lower limbs were found. The accidents, two repetitive miscarriages and positive anti-2GPi neurological examination revealed ataxic walk. Romberg antibodies. Skin biopsy specimens reveal inflammatory reflex was negative (-) and Babinski was positive (+) in changes of small- to medium-sized arteries and right. The ophthalmologic examination demonstrated an subendothelial proliferation and fibrosis. The diagnosis initial angiosclerosis. The dermatological examination Sneddon syndrome is confirmed by skin biopsy, and MR showed erythematous violaceous lesions with a reticular evidence. pattern, localized in the arms, trunk (Figure 1) thighs and We suggest that anti-2GPi antibodies may be knees (Figure 2, Figure 3). The following exams in the pathophysiologically related to the clinical manifestation laboratorial evaluation were normal or negative: blood count observed in some patients with Sneddon syndrome. -
Prognosis of a Case with Paresthesia Associated with Prolonged Touching of an Endodontic Paste to the Inferior Alveolar Nerve
J Clin Exp Dent. 2011;3(Suppl1):e377-81. Inferior alveolar nerve paresthesia. Journal section: Oral Surgery doi:10.4317/jced.3.e377 Publication Types: Case Report Prognosis of a case with paresthesia associated with prolonged touching of an endodontic paste to the inferior alveolar nerve M. Cemil Buyukkurt 1, Hakan Arslan 2, H. Sinan Topcuoglu 2, M. Melih Omezli 3 1 PhD, DDS. Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Sifa University, İzmir, Turkey 2 DDS. Department of Endodontic, Faculty of Dentistry, Ataturk University, Erzurum, Turkey 3 DDS. Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ataturk University, Erzurum, Turkey Correspondence: Department of Endodontic, Faculty of Dentistry, Ataturk University, Erzurum, 25240, Turkey E-mail address: [email protected] Received: 10/02/2011 Accepted: 08/05/2011 Buyukkurt MC, Arslan H, Topcuoglu HS, Omezli MM. Prognosis of a case with paresthesia associated with prolonged touching of an endodontic paste to the inferior alveolar nerve. J Clin Exp Dent. 2011;3(Suppl1):e377- 81. http://www.medicinaoral.com/odo/volumenes/v3iSuppl1/jcedv3iSu- ppl1p377.pdf Article Number: 50506 http://www.medicinaoral.com/odo/indice.htm © Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488 eMail: [email protected] Abstract Paresthesia is described as an abnormal sensation, such as burning, pricking, tickling, tingling, formication or num- bness. Several conditions can cause paresthesia. This article presents a case of paresthesia caused by the extrusion of endodontic paste (Endomethasone®) into the mandibular canal. The clinical manifestations comprised the numb- ness on the right side of the mandible and right lower lip, appearing after endodontic treatment. -
Pharmacotherapy of Neuropathic Pain: Which Drugs, Which Treatment Algorithms? Nadine Attal*, Didier Bouhassira
Biennial Review of Pain Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Nadine Attal*, Didier Bouhassira Abstract Neuropathic pain (NP) is a significant medical and socioeconomic burden. Epidemiological surveys have indicated that many patients with NP do not receive appropriate treatment for their pain. A number of pharmacological agents have been found to be effective in NP on the basis of randomized controlled trials including, in particular, tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitor antidepressants, pregabalin, gabapentin, opioids, lidocaine patches, and capsaicin high- concentration patches. Evidence-based recommendations for the pharmacotherapy of NP have recently been updated. However, meta-analyses indicate that only a minority of patients with NP have an adequate response to drug therapy. Several reasons may account for these findings, including a modest efficacy of the active drugs, a high placebo response, the heterogeneity of diagnostic criteria for NP, and an inadequate classification of patients in clinical trials. Improving the current way of conducting clinical trials in NP could contribute to reduce therapeutic failures and may have an impact on future therapeutic algorithms. Keywords: Neuropathic pain, Pharmacotherapy, Clinical trials, Therapeutic algorithms, Phenotypic subgrouping 1. Introduction Here, we briefly present the major pharmacological treatments studied in NP and the latest therapeutic recommendations for Neuropathic pain (NP) is estimated to affect as much as 7% of the general population in European countries19,83 and induces their use. We then outline the difficulties associated with a specific disease burden in patients.6,30,83 It is now considered pharmacotherapy of NP in clinical trials and draw prospects for as a clinical entity regardless of the underlying etiology.4 Epidemi- future drug trials and therapeutic algorithms.